Anti-Xa activity by weight in critically ill patients receiving unfractionated heparin for venous thromboembolism prophylaxis

被引:2
|
作者
Aggarwal, Meera, V [1 ]
Jarrell, Andrew S. [1 ]
Gilmore, Vi T. [1 ]
Aboagye, Jonathan K. [2 ]
Haut, Elliott R. [2 ,3 ,4 ,5 ,10 ]
Hobson, Deborah B. [2 ,3 ]
Lau, Brandyn D. [3 ,4 ,6 ,7 ]
Kickler, Thomas [8 ]
Kraus, Peggy S. [1 ]
Shaffer, Dauryne L. [2 ]
Shermock, Kenneth M. [1 ]
Streiff, Michael B. [3 ,9 ]
Zheng, Gang [8 ]
Kruer, Rachel M. [1 ]
机构
[1] Johns Hopkins Univ Hosp, Dept Pharm, 600 N Wolfe St Carnegie 180, Baltimore, MD 21287 USA
[2] Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21218 USA
[3] Armstrong Inst Patient Safety & Qual, Baltimore, MD USA
[4] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA
[5] Johns Hopkins Univ, Sch Med, Anesthesiol & Crit Care Med, Baltimore, MD 21218 USA
[6] Johns Hopkins Univ, Sch Med, Russell H Morgan Dept Radiol & Radiol Sci, Baltimore, MD 21218 USA
[7] Johns Hopkins Univ, Sch Med, Div Hlth Sci Informat, Baltimore, MD 21218 USA
[8] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21218 USA
[9] Johns Hopkins Univ, Sch Med, Dept Med, Div Hematol, Baltimore, MD 21218 USA
[10] Johns Hopkins Univ, Sch Med, Dept Emergency Med, Baltimore, MD 21218 USA
关键词
Heparin; Venous thromboembolism; Deep venous thrombosis; Prophylaxis; Anti-Xa; Obese; DOSE SUBCUTANEOUS HEPARIN; DEEP-VEIN THROMBOSIS; BARIATRIC SURGERY; PREVENTION; OBESE; ENOXAPARIN; EFFICACY; THROMBOPROPHYLAXIS; STRATEGIES; OVERWEIGHT;
D O I
10.1016/j.jcrc.2019.04.027
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Purpose: This study compared a nti-Xa activity in critically ill patients receiving UFH for VTE prophylaxis between two weight groups (<100 kg vs >= 100 kg). Methods: This prospective, observational study included critically ill patients on UFH 5000 or 7500 units every 8 h. A peak and trough anti-Xa activity assay was ordered for each patient at steady state. Goal peak anti-Xa activity was 0.1-0.3 units/mL. Results: From March 2017 to June 2018, 75 patients were enrolled with 44 in the <100 kg group and 31 in the >= 100 kg group. There was no significant difference in the percentage of patients with peak anti-Xa activity within goal range between patients <100 kg and >= 100 kg (55.3% vs 35.7%, p = 0.12). The odds ratio for achieving peak anti-Xa activity within goal range as weight-based dose increased was 1.03 (95% CI 0.99-1.07). No differences were found in trough anti-Xa activity, VTE, bleeding, length of stay, or death. Conclusions: Though only one-third of patients >= 100 kg had peak anti-Xa activity within goal range, no significant difference was found between the weight groups. Additional prospective studies with adequate sample sizes are warranted to further investigate appropriate weight-based dosing of UFH in critically ill patients. (C) 2019 Elsevier Inc. All tights reserved.
引用
收藏
页码:180 / 185
页数:6
相关论文
共 50 条
  • [21] Venous Thromboembolism Prophylaxis in Critically Ill Patients
    McLeod, Anne G.
    Geerts, William
    [J]. CRITICAL CARE CLINICS, 2011, 27 (04) : 765 - +
  • [22] Very low doses of unfractionated heparin potentiate the anti-Xa activity of low molecular weight heparin (Enoxaparin)
    PerezRequejo, JL
    LucenaSolano, O
    PerezGarcia, M
    Santarelli, MT
    [J]. THROMBOSIS AND HAEMOSTASIS, 1997, : P1172 - P1172
  • [23] Current DVT Prophylaxis Guidelines with Unfractionated Heparin (UFH) and Low Molecular Weight Heparin (LMWH) Are Inadequate for MICU Patients by Anti-Xa Levels
    Velasquez, A.
    Patel, H.
    Shaz, D.
    Perez, R. L.
    Leeper, K. V.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2009, 179
  • [24] Venous Thromboembolism Prophylaxis with Enoxaparin Versus Unfractionated Heparin in Patients with Low Body Weight
    Kaylor, David Michael
    Wade, Regan Merrell
    Chappell, Kathryn Brinkley
    Niemann, Meredith Huff
    VanArsdale, Vanessa Marie
    [J]. PLASMATOLOGY, 2023, 17
  • [25] Correlation between heparin anti-Xa activity and thromboelastography in adult critically ill COVID-19 patients
    Buckley, Mitchell S. S.
    Benanti, Grace E. E.
    Gilbert, Brian
    Meckel, Jordan
    Dzierba, Amy L. L.
    MacLaren, Robert
    [J]. PHARMACOTHERAPY, 2023, 43 (08): : 795 - 803
  • [26] Factors influencing enoxaparin anti-Xa activity in surgical critically ill patients
    Vincent, Philippe D.
    Albert, Martin
    Champagne, Marie-Christine
    Zikos, Theodora
    Boulanger, Isabelle
    Blais, Lucie
    Williamson, David R.
    [J]. JOURNAL OF CRITICAL CARE, 2011, 26 (04) : 347 - 351
  • [27] Comparison of low-molecular-weight heparin and unfractionated heparin for venous thromboembolism prophylaxis in trauma patients
    Gowler, Aimee
    Erstad, Brian
    Tang, Andrew
    [J]. PHARMACOTHERAPY, 2013, 33 (05): : E52 - E52
  • [28] Anti-factor Xa Activity Is Not Associated With Venous Thromboembolism in Critically Ill Patients Receiving Enoxaparin for Thromboprophylaxis: A Retrospective Observational Study
    Dibiasi, Christoph
    Gratz, Johannes
    Wiegele, Marion
    Baierl, Andreas
    Schaden, Eva
    [J]. FRONTIERS IN MEDICINE, 2022, 9
  • [29] Monitoring unfractionated heparin therapy: Lack of standardization of anti-Xa activity reagents
    Smahi, Motalib
    De Pooter, Neila
    Hollestelle, Martine J.
    Toulon, Pierre
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2020, 18 (10) : 2613 - 2621
  • [30] Puerperal thromboprophylaxis: comparison of the anti-Xa activity of enoxaparin and unfractionated heparin - Reply
    Greer, IA
    Walker, ID
    Gibson, JE
    Ekevall, K
    [J]. BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1999, 106 (06): : 615 - 615